Therapeutic efficacy of strontium-89-chloride for bone metastatic tumors without bone pain.
- Author:
Wei OUYANG
1
;
Jin-hua LIU
;
Wei-ying LIU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Bone Neoplasms; complications; radiotherapy; secondary; Female; Humans; Lung Neoplasms; pathology; Male; Middle Aged; Pain; etiology; Prostatic Neoplasms; pathology; Strontium Radioisotopes; therapeutic use; Treatment Outcome
- From: Journal of Southern Medical University 2007;27(3):390-391
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the safety and efficacy of strontium-89-chloride for management of bone metastases in patients without bone pain.
METHODSFifty-four patients without painful bone metastases were given a single intravenous dose (1.48-2.22 MBq/kg) of strontium-89-chloride, which was repeated once or twice at the interval between 3 and 6 months.
RESULTSThe total response rate was 74.0% in these, and the response rate was significantly lower in patients with focal size>2 cm than in those with focal size
CONCLUSIONStrontium-89-chloride is effective and safe for treatment of nonpainful bone metastases.
